EMPACT-MI: A streamlined multicentre randomised parallel group double-blind placebo-controlled superiority trial to evaluate the effect of Empagliflozin on hospitalisation for heart failure and mortality in patients with aCuTe Myocardial Infarction

Recruiting
99 years or below
All
1 Location

Brief description of study

TBD

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 25 May 2021. Study ID: 848701

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.